Page 5 - Promacta Revolade News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Promacta revolade. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Promacta Revolade Today - Breaking & Trending Today

Novartis AG (NYSE:NVS) - Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance

Novartis AG (NYSE:NVS) - Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Promacta Revolade ,

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

COVID-19 update
The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies in which Novartis operates. We continue to take strong actions to help address the pandemic. Our primary concerns remain the health and safety of our associates and patients.
There continues to be COVID-19 related lockdowns and disruptions in several geographies negatively impacting demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. For Sandoz, COVID-19 resulted in a historically weak cough and cold season and softened retail demand. At present, drug development operations are continuing with manageable disruptions (see the Innovation Review Section of the Condensed Interim Financial Report for further information), with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions. Our operations remain stable and ....

United States , New Zealand , Gleevec Glivec , Promacta Revolade , Afinitor Votubia , Exjade Jadenu , Muscular Dystrophy Association , Moody Investors Service , American College Of Cardiology , European Commission , Diovan Group , Swiss Exchange , Exforge Group , American Academy Of Neurology , Galvus Group , Sandoz Retail , Innovative Medicines , Medicines Index , Vas Narasimhan , For Sandoz , Innovation Review Section , Condensed Interim Financial Report , Molecular Partners , Established Medicines , Emerging Growth Markets , Western Europe ,

Novartis Pharma AG: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

Novartis Pharma AG: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , New Zealand , Gleevec Glivec , Promacta Revolade , Afinitor Votubia , Exjade Jadenu , Muscular Dystrophy Association , Moody Investors Service , Novartis Group , American College Of Cardiology , European Commission , Diovan Group , Swiss Exchange , Exchange Commission , Exforge Group , American Academy Of Neurology , Galvus Group , Sandoz Retail , Innovative Medicines , Medicines Index , Vas Narasimhan , For Sandoz , Innovation Review Section , Condensed Interim Financial Report , Molecular Partners , Established Medicines ,

Novartis (NVS) Q1 2021 Earnings Call Transcript

Novartis (NVS) Q1 2021 Earnings Call Transcript
Motley Fool Transcribing
© The Motley Fool
Logo of jester cap with thought bubble.
Novartis (NYSE: NVS)
Good morning and good afternoon, and welcome to the Novartis Q1 2021 results release conference call and live audio webcast. Please note that during the presentation, all participants will be on a listen-only mode and the conference is being recorded. [Operator instructions] A recording of the conference call including the Q&A session will be available on our website shortly after the call ends. [Operator instructions] With that, I would like to hand it over to Mr.
Samir Shah, global head of investor relations. Please go ahead, sir. ....

United States , Czech Republic , Graham Parry , Matthew Weston , Andrew Baum , Susanne Schaffert , Laura Sutcliffe , Harry Kirsch , Samir Shah , Andrew Baum Citi , Simon Baker Redburn , Keyur Parekh , Mike Nedelcovych , Tom Kendris , John Tsai , Richard Parkes , Tim Anderson , Florent Cespedes , Richard Wagner , Societe Generale , Richard Parkes Exane , Florent Cespedes Societe Generale , Mark Purcell , Simon Baker , Exjade Jadenu , Emmanuel Papadakis ,

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

13
1Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
2Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
3 Please see detailed guidance assumptions on page 8 including the forecast assumption that we see a continuation of the return to normal global healthcare systems including prescription dynamics by mid 2021. In addition, we assume that no Gilenyaand noSandostatinLAR generics enter in 2021 in the US. ....

United States , Charlesl Sawyers , Bridgette Heller , Bertrand Bodson , Kesimptaandentresto Hfp , Robert Weltevreden , Elizabeth Doherty , Patrice Bula , Nancyc Andrews , Jakavi Gv , Simon Moroney , Promacta Revolade , Frans Van Houten , Joerg Reinhardt , Srikant Datar , Enrico Vanni , Moody Investors Service , Novartis Group , Compensation Committee , Customer Technology Solutions , Novartis Executive Committee On , Alcon Inc , Committee Novartis , Sandoz Division , Committee Of Novartis , International Financial Reporting Standards ,